According to the GRADE method and summary of the results, experts drew up 46 statements. Of these guidelines, 5 had a high level of evidence (GRADE 1 ±), 21 had a low level of evidence (GRADE 2±), and 20 were expert opinions. A strong agreement was reached for all statements after two rounds of scoring.
Psychological care, sleep, pain, agitation, delirium and in severe and critical adult patients with COVID-19
Rationale Besides experiencing physical impairment and stressful treatments, COVID-19 patients are being subjected to closing monitoring, and are also witnessing various events in the ward such as sudden deterioration of illness, emergency resuscitation procedures and death, all of which could lead to posttraumatic stress disorder, anxiety, and depression according to previous studies [
88,
89]. It was reported that 10% to 18% of SARS survivors had symptoms related to posttraumatic stress disorder, anxiety, and depression and that emotional support, such as communication with others and sharing worries could reduce symptom severity [
88]. Accordingly, psychological implications should not be ignored in coronavirus patients. Psychological health services and humanistic care could have an important role in rehabilitation. The previous study confirmed that citalopram could improve reappraisal ability and anxiety symptoms in children and adolescents [
90] and that olanzapine could improve psychotic symptoms [
91]. Therefore, citalopram or olanzapine should probably be used to improve the psychological symptoms in patients or intervention of the psychologists in the isolation ward who would perform psychological assessment and psychotherapy for patients with new coronary pneumonia.
Rationale Sleep abnormalities, including abnormal sleep architecture, sleep deprivation, and disruption, frequently occur in the ICU. Numerous factors can affect sleep in COVID-19 patients, such as stress, anxiety, pain, respiratory distress, tachypnea from the underlying hypoxemia, noise levels, stage lighting in the isolation ward, implementation of healthcare, procedures of healthcare workers, and the pathophysiology of the acute illness. Sleep abnormalities may not only lead to mental disorders, but could also damage tissue repair, immune regulation mechanisms and cause delirium, all of which are associated with patient’s poor prognosis [
92,
93]. Nonpharmacological strategies for preventing sleep disturbances and treating delirium, such as keeping noise levels within 44 and 45 dB range (A) during the day, and less than 35 dB (A) at night [
94,
95], and providing critical patients admitted to the ICU with earplugs can significantly improve patient’s sleep and reduce the risk of delirium [
96]. However, in patients with sleep disturbances and delirium, pharmacotherapy care may be necessary. Medications such as dexmedetomidine [
97] and melatonin [
98,
99] may promote sleep and decrease the incidence of delirium, although only limited data are available in support of their use [
100].
Rationale Pain is defined as an uncomfortable physical and mental experience caused by physical injury, inflammation, or emotional stimuli. COVID-19 patients tend to experience pain due to hypoxia, long-term immobility, inflammatory storm, impairment of heart, liver, kidney, and other organ functions, procedures, and mental stress. Opioids, such as remifentanil and sufentanil, are the first-line options for analgesia in ICU according to the pain, agitation/sedation, delirium, immobility, and sleep disruption (PADIS) guidelines [
101]. Sufentanil can be used for COVID-19 patients receiving invasive mechanical ventilation during the early stage of severe ARDS because of its stronger and faster onset of analgesia, and small accumulation [
102]. Remifentanil is suitable for COVID-19 patients receiving invasive mechanical ventilation, especially during person–ventilator confrontation [
103] due to stronger respiratory depression. Previous research has confirmed that music or relaxation may diminish anxiety and discomfort in some patients [
104,
105]. Therefore, nonpharmacological pain management strategy can be used for conscious patients with COVID-19 or for patients who do not tolerate opioid therapy, such as COVID-19 patients receiving HFNC oxygen therapy or non-invasive mechanical ventilation.
Assessment of the patient’s pain is the foundation of pain management. Accordingly, a numeric rating scale (NRS) should probably be used for evaluation of pain in all COVID-19 patients able to self-report their pain. Behavioral pain scale (BPS) and critical-care pain observation tool (CPOT) should be used to evaluate pain in critically ill patients unable to express the pain for themselves. The ideal target values are: NRS < 4 points, BPS < 5 points and CPOT < 3 points.
Rationale It is well known that analgesia and sedation can eliminate pain and discomfort, reduce sympathetic nerve excitement, patient’s metabolic rate, oxygen consumption, the metabolic burden of various organs, stress, and inflammation. However, plenty of evidence suggests that deep sedation is associated with adverse outcomes, including prolonged mechanical ventilation and ICU-stay, higher mortality, lower rates of in-hospital, and 2-year follow-up survival [
106‐
110]. Under ‘real-life’ conditions in Wuhan, deep sedation was extremely important for reducing oxygen consumption and developing tolerance to mechanical ventilation by new coronavirus patients with severe ARDS who suffered from respiratory distress, tachypnea and respiratory overdrive even after receiving invasive mechanical ventilation. Accordingly, deep sedation should be an important part of lung-protective ventilation strategy, especially during the early stage of severe ARDS. Previous studies have confirmed that daily spontaneous awakening trials (interruption of sedatives) lead to better outcomes in patients receiving mechanical ventilation [
111]. However, critically ill patients with COVID-19 have a longer mechanical ventilation time, and daily sedatives interruption is not suggested for patients receiving deep sedation in order to reduce lung damage during early stage of severe ARDS.
Midazolam and propofol are the primary medications used for ICU deep sedation. The Sedation–Agitation Scale (SAS) and RASS are the reliable and valid sedation assessment tools used for assessing the depth and quality of sedation in COVID-19 patients. The SAS and RASS should be used to measure the depth after administering sedatives. The target value is RASS -3–4 points, SAS 2 points for deep sedation, and SAS 1 point. The target value of very deep sedation is RASS -5 point for patients receiving neuromuscular blocking agents [
112], prone position, or ECMO treatment. We suggest a bispectral index monitoring for patients undergoing very deep sedation, if available.
Rationale Agitation and anxiety, which frequently occur in COVID-19 patients, may be associated with adverse outcomes. Appropriate sedation can reduce anxiety and agitation while preserving patients’ comfort. Light sedation can maintain frequent redirection, and increase the physiologic stress response, but not increase the incidence of myocardial ischemia. We suggest the use of light sedation for COVID-19 patients receiving HFNC oxygen therapy or non-invasive mechanical ventilation. In addition, light sedation should be given to recovering patients in order to reduce the time of mechanical ventilation and the time of stay in ICU [
113] when PaO
2/FiO
2 ≥ 150–200 mmHg.
Dexmedetomidine can be used for patients receiving light sedation due to the small respiratory depression. The target value of light sedation is SAS 3–4 points and RASS − 2 to +1 points.
Secondary infection
Great attention should be paid to secondary infection since it may worsen the patient’s prognosis. However, since the data on the epidemiology of secondary infection in COVID-19 patients are lacking, we can only make some suggestions according to our own experience and some previous studies focused on H1N1.
Rationale Due to the nature of virus infection, it is not logical to use prophylactic antibiotics, and there is no evidence that this strategy could reduce the incidence of the secondary infection. On the other hand, according to the management guidelines of COVID-19 from WHO and China [
3,
6], empiric antibiotic treatment should only be used based on the clinical diagnosis (community-acquired pneumonia, healthcare-associated pneumonia or sepsis), local epidemiology and susceptibility data, and treatment guidelines. Based on our observations from Wuhan, many severe and critical COVID-19 patients did not show any signs of bacterial infection (such as elevated WBC, PCT and similar); thus, we do not suggest the routine use of prophylactic antibiotics in COVID-19 patients, especially at the early stage or for non-intubated patients.
Rationale Both long course of the disease and immunosuppressive state place the severe and critical COVID-19 patients at a high risk of secondary infection (including bacteria and fungus). Unfortunately, the data on the epidemiology of secondary infection in COVID-19 patients are lacking. However, based on the evidence from H1N1, secondary infection is very common in patients admitted to ICU > 48 h [
120,
126]. Although a complete nosocomial infection prevention and control system was set up in Wuhan according to the guidelines [
127,
128], ventilator-associated pneumonia and hospital acquired pneumonia were very common occurrences in the ICU. We suspect this is mainly because the medical staff is wearing heavy personal protective equipment, and heavy workload adhered to the incomplete implementation of these measures. Consequently, the strategies for nosocomial infection prevention should be effectively implemented, and multiple site samples (blood, sputum, etc.) should be routinely collected to monitor the signs of secondary infection.
Diagnosis and treatment of COVID-19-associated coagulopathy
In clinical practice, coagulation dysfunction is commonly found in COVID-19 patients, and the symptoms range from mild disorders of coagulation indicators to disseminated intravascular coagulation (DIC). The exact etiology of COVID-19-associated coagulopathy is unclear, diverse and multifactorial, and may include direct attack by the SARS-CoV-2 on vascular endothelial cells, cytokine storm-mediated inflammation–coagulation cascades, hypoxia, and complication with sepsis. Coagulation dysfunction or thrombocytopenia is closely associated with the severity and poor prognosis in COVID-19 patients [
129]. Clinicians should increase awareness of COVID-19-associated coagulopathy, which in COVID-19 patients is accompanied with the following abnormal coagulation indexes: platelet–lymphocyte ratio < 100 × 10
9, the reduction of prothrombin time (PT) and activated partial thromboplastin time (APTT) by more than the lower limit of 99th percentile or the increase of PT by more than 3 s or APTT by more than 5 s, or the increase of fibrinogen, fibrin degradation product (FDP) and D-dimer by more than the lower limit of 99th percentile without clinical evidence of primary blood system diseases or chronic liver diseases.
Rationale According to the available literature, the condition of COVID-19 patients is commonly complicated with coagulopathy, where the symptoms range from mild disorders of coagulation indicators to DIC. The increase of D-dimer in COVID-19 patients is very common, accounting for 36% to 46.4% of all cases [
15,
60,
64,
130,
131]. The degree of elevation and persistent elevation are indicators of poor prognosis. The Nanshan Zhong team has reported that among 1099 COVID-19 patients in 552 hospitals from 31 provinces (926 mild cases and 173 severe cases), the proportion of severely ill patients with D-123dimer higher than 0.5 mg/L was up to 59.6%, and the proportion for the mild patients was 43.2% [
60]. Zhou et al. have demonstrated that among 191 confirmed COVID-19 patients (54 deaths, 171 survival), D-dimer > 1.0 g/L was an independent risk factor for clinicians to identify patients with poor prognosis at the early stage [
130]. The coagulation parameters (PT and APTT) in COVID-19 patients vary with different severity and the different courses of the disease. COVID-19 patients in the early stage show the activation of the exogenous coagulation system, manifested as decreased PT and hypercoagulable state. Along with the progression of the disease, especially when patients develop DIC, PT and APTT significantly increase, which is associated with the poor prognosis of patients. Tang has reported increased fibrinogen (5.16 g/L vs. 4.51 g/L,
P = 0.149) and FDP values (7.6 µg/mL vs. 4 µg/mL,
P < 0.001) in COVID-19 patients [
131], which indicated that instead of hyperfibrinolysis observed in the late stage of DIC, fibrinolysis inhibition is the main feature accompanying the progression of COVID-19. The autopsies of COVID-19 patients have revealed abundant transparent thrombus in the pulmonary alveoli, myocardium, portal area, and renal tubular epithelial cells, thus indicating that fibrinolysis inhibition may have a decisive role in COVID-19-associated coagulation dysfunction.
The incidence of DIC is low in COVID-19 patients. It has been reported that among the 1099 COVID-19 patients, only 1 patient (0.1%) was diagnosed as DIC [
60]. However, Tang’s report has shown that the overall incidence of DIC is 8.74%. The existence of DIC was more common in fatal cases, where 71.4% met the ISTH diagnostic criteria for DIC; the median time for DIC diagnosis after admission was 4 days, whereas among the patients who survived, only 1 patient (0.6%) met this criterion [
131].
Medical institutes should dynamically detect the PT, international normalized ratio (INR), APTT, D-dimer, fibrinogen, and FDP to identify COVID-19-associated coagulation disorders, which might be helpful for making timely treatment decisions. It is also suggested to use the ISTH score system to diagnose COVID-19-associated DIC [
132]; if possible, SF and PAI-1 should be used to detect the pre-DIC status in the shortest possible time.
Rationale The most common clinical features of coagulopathy in COVID-19 patients are thrombosis in the deep vein or intermuscular vein of the lower extremity, which can be identified by the coagulation parameters and ultrasonic monitoring. It has been reported that the incidence of VTE or thrombotic complications in patients with severe COVID-19 admitted in the ICU was 25–31% [
133,
134]. It is necessary to pay attention to the clinical observation of patients with bed rest lasting for more than 3 days and observe whether these patients are experiencing asymmetric pain, swelling or discomfort in unilateral lower limbs or bilateral lower limbs, or local swelling or superficial vein filling in the lateral limbs. Especially when patients show chest pain, hemoptysis, dyspnea, or hypoxemia, which cannot be explained by NCP or other basal diseases, we should be alert to the occurrence of pulmonary thromboembolism.
For critically ill COVID-19 patients with low hemorrhage risk, a subcutaneous injection of LMWH should probably be used for the prevention of VTE. For patients with severe renal dysfunction (creatinine clearance rate < 30 mL/min), unfractionated heparin is recommended. For critically ill patients whose condition is complicated with high hemorrhage risk, intermittent pneumatic compression is recommended for mechanical prevention. Mild or moderate COVID-19 patients should probably avoid sedentary lifestyle or dehydration and are encouraged to engage in active activities and to drink more water appropriately. For mild or moderate COVID-19 patients with a high or moderately high risk of VTE according to the Padua or Caprini evaluation model, it should probably be considered to use LMWH for 7 to 10 days until the elimination of risk factors.
Rationale Hypercoagulant state is common in COVID-19 patients. Meantime, cytokine storm-mediated inflammation–coagulation cascades may have an essential role in COVID-19-associated coagulopathy. Studies have found that in addition to the anticoagulant effect, heparin also has a certain anti-inflammatory effect [
135]. Therefore, LMWH or unfractionated heparin is the first choice for anticoagulation: Tang et al. have reported that LMWH or unfractionated heparin anticoagulation was associated with improved survival in the patients with a sepsis-induced coagulopathy (SIC) score ≥ 4 and in those with D-dimer levels more than 6 times of the upper limit of normal(≥ 3 mg/L) [
136]. It is suggested that LMWH 100 U/kg or unfractionated heparin 5000 units subcutaneously twice daily could be given to patients without contraindication once D-dimer ≥ 3 mg/L or SIC ≥ 4. Heparin-induced thrombocytopenia (HIT) should be prevented during heparin treatment, and platelet counting should be monitored daily. For patients with HIT, other anticoagulants, such as agatraban, bevaludine, fondaparinux, and rivaroxaban, could be used. For patients at high risk of bleeding, anticoagulants are not recommend, and Chinese traditional medicine could be used to improve blood circulation and dispersing stasis.
Diagnosis and treatment of COVID-19-associated AKI
Although diffuse alveolar damage and ARDS are the main features of COVID-19, the involvement of the kidney and other organs needs to be considered. AKI was associated with a higher risk of in-hospital mortality. Clinicians should increase awareness of AKI in hospitalized COVID-19 patients.
Rationale The incidence of AKI in COVID-19 patients varies with different severity of illness: mild cases have an AKI incidence of 0.1–2%, severe cases have an AKI incidence of 3–3.2%, and the AKI incidence for those critical cases that require to be admitted in ICU is up to 8.3–29% [
5,
15,
64,
137,
138].
According to KDIGO AKI diagnostic criteria, certifying AKI is mainly based on changes in sCr, and the frequency of sCr tests has a substantial impact on the detection rate of AKI. In a nationwide cross-sectional survey of hospitalized adult patients in China, the detection rate of AKI was only 0.99% by KDIGO criteria [
139]. After adjusting for the frequency of sCr, the incidence of AKI in Chinese hospitalized adults rose to 11.6% [
140]. Thus, in order to improve early recognition of AKI, sCr measurements should be performed more frequently throughout the course of the disease. It is necessary to measure sCr every 2 days throughout the course of the disease to avoid a missed diagnosis of AKI.
Rationale The exact pathogenesis of COVID-19 associated AKI is unclear. The etiology of kidney impairment in COVID-19 patients, which is likely to be diverse and multifactorial, may include direct attack by the SARS-CoV-2 on target cells in the kidney, immune system-mediated damage, disease-related prerenal factors, a complication with sepsis and nephrotoxic drug-related factors [
137,
141]. COVID-19 associated AKI is an independent risk factor for poor prognosis in patients. Clinicians should address standard AKI following 5R principle (Risk screen, Recognition in the early phase, Response in time, Renal replacement therapy, and rehabilitation of the kidney). AKI is significantly more likely to develop in severe COVID-19 patients than in non-severe patients [
5,
15,
64,
137,
138]. Meanwhile, studies have shown that patients with elevated baseline sCr are more likely to develop AKI and develop more severe AKI [
137]. Therefore, we should routinely screen the risk of AKI in COVID -19 patients, particularly for severe cases, patients with elevated baseline sCr or those having proteinuria and hematuria at admission. Optimizing the volume status and oxygenation, maintaining hemodynamic stability, making sure the mean blood pressure above 65 mmHg are the important measures for prevention and treatment of AKI.
Rationale According to the available literature [
5,
15,
64,
137,
138], the percentage of COVID-19 patients who require continuous renal replacement therapy (CRRT) is 1.5–9%, and particularly the percentage of critical patients admitted in ICU that requires CRRT is 5.6–23.0%. Indications of the CRRT in COVID-19 patients include renal indications and non-renal indications. Renal indications include severe AKI (KIDGO AKI 2–3 stages) with hemodynamic instability. Non-renal indications include complications with severe ARDS and persistent inflammatory fever, which cannot be controlled not even with glucocorticoid corticosteroid therapy, hypernatremia refractory to conservative medical treatment, volume overload or urine output, which cannot meet the needs of drug infusion and energy supply and diuretic resistance.
Multiple RCT research has indicated that the application of CRRT in critical patients in an early phase cannot effectively decrease the mortality rates [
142,
143]. However, considering the suggestion that restrictive fluid volume management strategy should be adopted for COVID-19 patients complicated by ARDS based on the premise of sufficient tissue perfusion, we suggest CRRT initiation in severe patients within 24 h when they show rank 2 AKI under KDIGO criteria or accompanied with cytokine storm syndrome. In clinical practice, the doctors in charge should comprehensively evaluate conditions including the COVID-19 patient’s level of systemic inflammation, severity and progress of illness, severity, and progress of AKI, local medical resources, and the qualification of blood purification operators to give a reasonable choice of CRRT application.
Rational CRRT prescription should be prescribed before the application of CRRT on patients, and the prescription must be target-oriented. Continuous veno-venous hemofiltration (CVVH)\continuous veno-venous hemodiafiltration (CVVHDF) is the common CRRT mode to resolve severe disturbance of electrolyte and acid–base balance and correcting azotemia, while slow continuous ultrafiltration (SCUF) could be adapted for fluid overload alone.
A high proportion of critical COVID-19 patients show hypercoagulable state. Reports show that for COVID-19 patients, their APTT and PT are shortened by 16% and 30%, respectively, and 36% of patients show an increase of D-dimer concentration [
131]. The autopsy pathology of COVID-19 patients displayed lots of transparent thrombus in the pulmonary alveoli, myocardium, portal area, and renal tubular epithelial cells [
63]. So anticoagulation treatment with heparin should be applied with priority for patients with no or low risk of bleeding. For critical patients with active bleeding or with a high risk of bleeding, we suggest regional citrate anticoagulation (RCA) or anticoagulation without heparin. As ECMO uses systemic heparinization, no independent usage of anticoagulant is required in CRRT combined with ECMO treatment [
144].
Nutritional support therapy in severe and critically ill adult patients with COVID-19
COVID-19 patients may present with fever, fatigue, and dry cough. Critical patients often develop dyspnea and/or hypoxemia after 1 week, and, later on, may develop acute respiratory distress syndrome, shock, etc. [
6]. These patients are believed to suffer from malnutrition, which is linked to three different factors [
145]: (1) a severe catabolic state with marked proteolysis and loss of lean body mass because of stress and inflammation. As the need for energy and protein increases, negative nitrogen balance often occurs. (2) In severe COVID-19 patients, the gastrointestinal function is impaired due to hypoxia and novel coronavirus infection. Clinically, some patients suffered from anorexia and diarrhea due to virus attack, antiviral drugs such as lopinavir/ritonavir, and anti-infective drugs. (3) Some patients receiving noninvasive mechanical ventilation are at risk of enteral nutritional intolerance and aspiration for severe abdominal distension and increased intra-abdominal pressure through ventilation. Therefore, severe and critically ill COVID-19 patients are often at high nutritional risks, particularly those with underlying diseases and the elderly or who were hospitalized in ICU for more than 48 h [
145].
Rationale One of the metabolic characteristics of COVID-19 patients is increased proteolysis and change in the amino acid spectrum. Clinical tests showed that the levels of branched-chain amino acids are decreased, and the serum pre-albumin level is often < 100 mg/L (is some cases even lower than 70 mg/L, or < 50 mg/L). NRS 2002 or the modified NUTRIC scoring tool [
146] has been recommended for these patients; NRS 2002 score ≥ 3 indicates malnutrition risk, and nutrition intervention is required. For patients with high malnutrition risk who have an NRS2002 score ≥ 5 or a modified NUTRIC score ≥ 5 (without considering IL-6), nutritional therapy should be prescribed as soon as possible. For patients admitted to the ICU for more than 48 h, a nutritional risk assessment should be initiated as quickly as possible.
Rationale A meta-analyses [
147] showed that a moderately hypocaloric (enteral) diet (provisioning of 50–70% of the calorie target) was superior to a severely hypocaloric diet (provisioning of about 30% of the calorie target). When analyzing the magnitude of calorie intake (severely vs. moderately hypocaloric), three meta-analyses suggested that a severely hypocaloric diet may be harmful in the acute phase.
Enteral nutrition (EN) is the preferred route of feeding for critically ill patients who require nutrition support therapy and cannot normally eat [
148,
149].
Society of parenteral and enteral nutrition of China medical association has recommended five-step method to implement nutrition therapy for COVID-19 patients: elemental diet, nutrition education, oral nutritional supplement, tube feeding for EN, supplemental parenteral nutrition, parenteral nutrition (PN) and total parenteral nutrition (TPN).
Medical nutrition therapy should be initiated within the first 24 h after ICU admission in those patients who are unable to maintain sufficient volitional intake during the early acute phase of critical illness [
148,
150].
Initiate EN within 24–48 h following the onset of critical illness and admission to the ICU, and increase to goals over the first week of ICU-stay.
For patients with invasive mechanical ventilation or receiving ECMO, if there is no contraindication of enteral nutrition, enteral nutrition is recommended as early as possible.
Enteral nutrition should be delayed in patients with severe COVID-19 with shock, severe hypoxia, severe acidosis, upper gastrointestinal hemorrhage or residual in stomach > 500 mL/6 h, intestinal ischemia, intestinal obstruction, and abdominal compartment syndrome.
Rationale Part of COVID-19 patients show symptoms like diarrhea. Some severe patients with intestinal dysfunction are prone to enteral nutrition intolerance. For feeding intolerance, healthy feeding should be considered (feeding speed: 10–20 kcal/h or 10–30 mL/h). It is recommended to achieve a feeding target as 25–30 kcal/kg/d. At the same time, it is recommended that protein should be supplied by 1.5–2.0 g/kg/d (nitrogen 0.25–0.33 g/kg/d). The supply of branched-chain amino acids should be increased for promoting protein synthesis. When the protein intake is insufficient, it is recommended to add protein powder based on standard protein preparations to improve respiratory muscle function and immune function. In parenteral nutrition, the non-protein energy supply ratio: sugar/fat ratio is 50–70/50–30. Patients with severe COVID-19 and ARDS should appropriately reduce the proportion of sugar when selecting the type of enteral nutrition preparation in order to reduce the production of carbon dioxide. At the same time, because strict fluid management principles are used in these patients, it is recommended to choose high-energy-density enteral nutrition preparations in the early stage to limit excessive fluid intake.
Rationale Severe COVID-19 patients often have trouble eating because the gastrointestinal function is impaired due to hypoxia and novel coronavirus infection. Therefore intestinal nutrition tube indwelling is should probably be used for these patients. Most of the patients with severe COVID-19 are elderly or with other comorbidities. The factors that increase the risk of aspiration are as follows: poor airway protection, aged > 70 years old, decreased level of consciousness, poor oral care, gastroesophageal reflux, and lack of nursing manpower due to the severe outbreak of COVID-19 in China. For these patients, post-pylorus feeding should be chosen. Jejuna feeding has shown to be associated with a lower rate of ventilator-associated pneumonia (< 30%) and should be delivered as a continuous infusion [
149]. For those patients without a high risk of aspiration, the gastric tube should be used first because it is easy to implement.
On the other hand, for patients using non-invasive ventilation, nasal mask during feeding should probably be used to reduce the risk of hypoxemia. For those using a gastric tube, it is recommended to use the “button” mask because this type of mask is equipped with a gastric tube outlet without affecting the efficiency of ventilation. However, if patients with NIV suffer from severe abdominal distension because of severe flatulence, post-pyloric feeding should be selected. For those patients using invasive ventilation, gastric tube indwelling is recommended. However, if patients are under prone position, ventilation, feeding using a jejunal nutrient canal should be recommended.